Spearhead Capital Advisors’s AbbVie ABBV Stock Holding History

Spearhead Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$952K	Sell	7,093 -57,868	-89%	-$8.3M	1.03%	31
2022 Q2	$9.95M	Sell	64,961 -15,510	-19%	-$2.37M	1.48%	20
2022 Q1	$13M	Sell	80,471 -4,457	-5%	-$647K	1.62%	18
2021 Q4	$11.5M	Buy	84,928 +2,296	+3%	+$271K	1.39%	22
2021 Q3	$8.91M	Buy	82,632 +10,880	+15%	+$1.24M	1.19%	41
2021 Q2	$8.08M	Buy	71,752 +1,524	+2%	+$172K	1.1%	48
2021 Q1	$7.6M	Buy	70,228 +1,540	+2%	+$165K	1.12%	52
2020 Q4	$7.36M	Buy	68,688 +6,116	+10%	+$588K	1.17%	29
2020 Q3	$5.48M	Buy	62,572 +1,209	+2%	+$114K	1.05%	44
2020 Q2	$6.03M	Buy	61,363 +3,570	+6%	+$314K	1.29%	23
2020 Q1	$4.4M	Sell	57,793 -199	-0.3%	-$16.9K	1.27%	35
2019 Q4	$5.13M	Sell	57,992 -794	-1%	-$65.9K	1.28%	33
2019 Q3	$4.45M	Buy	58,786 +7,714	+15%	+$529K	1.24%	38
2019 Q2	$3.71M	Buy	51,072 +6,712	+15%	+$528K	1.09%	53
2019 Q1	$3.58M	Buy	44,360 +9,335	+27%	+$764K	1.08%	48
2018 Q4	$3.23M	Sell	35,025 -1,484	-4%	-$131K	1.38%	29
2018 Q3	$3.46M	Buy	36,509 +1,132	+3%	+$107K	1.16%	41
2018 Q2	$3.28M	Buy	35,377 +2,835	+9%	+$277K	1.17%	35
2018 Q1	$3.08M	Buy	32,542 +5,176	+19%	+$569K	1.2%	35
2017 Q4	$2.65M	Buy	+27,366	New	+$2.58M	1.29%	31

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Spearhead Capital Advisors's ABBV Position: Q3 2022 in Review

Spearhead Capital Advisors reduced its AbbVie (ABBV) stake by 89% in Q3 2022, selling an estimated $8.3M and leaving 7,093 shares worth $952K. The position accounts for 1.03% of the portfolio, ranked #31.

Spearhead Capital Advisors first reported a position in ABBV in Q4 2017 and has held it in 20 quarters since. The position peaked at $13M in Q1 2022. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Spearhead Capital Advisors held 7,093 shares of AbbVie worth $952K as of Q3 2022.
Spearhead Capital Advisors sold 57,868 AbbVie shares in Q3 2022, an estimated $8.3M.
AbbVie made up 1.03% of Spearhead Capital Advisors's portfolio in Q3 2022, its #31 holding.
Spearhead Capital Advisors first reported a position in AbbVie in Q4 2017 and has held it in 20 quarters since.
Spearhead Capital Advisors's AbbVie position peaked at $13M in Q1 2022.
2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.